SciSparc (SPRC) Competitors $4.23 +0.01 (+0.24%) Closing price 04:00 PM EasternExtended Trading$4.23 0.00 (0.00%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock SPRC vs. DWTX, BFRI, APRE, KPRX, ENTO, TLPH, EVOK, CLDI, MTNB, and SNOAShould you be buying SciSparc stock or one of its competitors? The main competitors of SciSparc include Dogwood Therapeutics (DWTX), Biofrontera (BFRI), Aprea Therapeutics (APRE), Kiora Pharmaceuticals (KPRX), Entero Therapeutics (ENTO), Talphera (TLPH), Evoke Pharma (EVOK), Calidi Biotherapeutics (CLDI), Matinas Biopharma (MTNB), and Sonoma Pharmaceuticals (SNOA). These companies are all part of the "pharmaceutical products" industry. SciSparc vs. Its Competitors Dogwood Therapeutics Biofrontera Aprea Therapeutics Kiora Pharmaceuticals Entero Therapeutics Talphera Evoke Pharma Calidi Biotherapeutics Matinas Biopharma Sonoma Pharmaceuticals SciSparc (NASDAQ:SPRC) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings. Do institutionals & insiders have more ownership in SPRC or DWTX? 25.1% of SciSparc shares are owned by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are owned by institutional investors. 1.5% of SciSparc shares are owned by company insiders. Comparatively, 3.9% of Dogwood Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media favor SPRC or DWTX? In the previous week, Dogwood Therapeutics had 7 more articles in the media than SciSparc. MarketBeat recorded 10 mentions for Dogwood Therapeutics and 3 mentions for SciSparc. SciSparc's average media sentiment score of 1.01 beat Dogwood Therapeutics' score of 0.09 indicating that SciSparc is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SciSparc 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dogwood Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation & earnings, SPRC or DWTX? SciSparc has higher revenue and earnings than Dogwood Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSciSparc$1.31M1.71-$6.28MN/AN/ADogwood TherapeuticsN/AN/A-$12.35M-$18.78-0.26 Which has more volatility & risk, SPRC or DWTX? SciSparc has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Dogwood Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Is SPRC or DWTX more profitable? Company Net Margins Return on Equity Return on Assets SciSparcN/A N/A N/A Dogwood Therapeutics N/A N/A -27.41% Do analysts recommend SPRC or DWTX? Dogwood Therapeutics has a consensus price target of $10.00, indicating a potential upside of 102.63%. Given Dogwood Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dogwood Therapeutics is more favorable than SciSparc.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SciSparc 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Dogwood Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryDogwood Therapeutics beats SciSparc on 6 of the 11 factors compared between the two stocks. Get SciSparc News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRC vs. The Competition Export to ExcelMetricSciSparcMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.24M$2.47B$5.73B$9.76BDividend YieldN/A1.68%4.40%4.08%P/E RatioN/A22.5330.3826.03Price / Sales1.71558.65428.56103.94Price / CashN/A26.0925.7828.79Price / Book0.235.609.706.08Net Income-$6.28M$32.94M$3.27B$265.64M7 Day Performance-6.21%3.13%3.95%3.11%1 Month Performance-41.82%1.01%3.81%0.39%1 Year Performance-49.01%5.14%31.26%18.52% SciSparc Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRCSciSparc1.3222 of 5 stars$4.23+0.2%N/A-45.2%$2.24M$1.31M0.004News CoveragePositive NewsGap UpHigh Trading VolumeDWTXDogwood Therapeutics1.7656 of 5 stars$4.98-6.0%$10.00+100.8%N/A$9.51MN/A-0.275BFRIBiofrontera3.0715 of 5 stars$0.93flat$2.75+195.7%-21.9%$9.43M$37.32M-0.4170News CoverageGap UpAPREAprea Therapeutics2.8892 of 5 stars$1.59-3.6%$15.50+874.8%-54.4%$9.27M$1.50M-0.697KPRXKiora Pharmaceuticals2.7212 of 5 stars$2.69-6.6%$10.00+271.7%-29.7%$9.23M$16.02M-0.9210Gap UpENTOEntero TherapeuticsN/A$1.93-10.6%N/A+65.9%$9.21MN/A0.009Gap DownTLPHTalphera2.292 of 5 stars$0.45+3.6%$5.00+1,016.1%-36.2%$9.18M$650K-1.1219Gap UpHigh Trading VolumeEVOKEvoke Pharma0.3158 of 5 stars$6.13+2.9%N/A+17.9%$9.15M$12.79M-2.394News CoverageGap DownCLDICalidi Biotherapeutics0.7167 of 5 stars$3.00-26.8%N/A-88.4%$9.08MN/A0.0038Insider TradeGap UpMTNBMatinas Biopharma0.6962 of 5 stars$1.70-0.6%N/AN/A$8.65MN/A-0.3530SNOASonoma PharmaceuticalsN/A$5.23-2.2%N/A+1,895.9%$8.59M$14.91M-2.13180Gap Down Related Companies and Tools Related Companies DWTX Alternatives BFRI Alternatives APRE Alternatives KPRX Alternatives ENTO Alternatives TLPH Alternatives EVOK Alternatives CLDI Alternatives MTNB Alternatives SNOA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRC) was last updated on 8/26/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s national nightmare is hereWhile the headlines focus on global conflicts, there’s a very different crisis brewing at home. Washington has...Porter & Company | SponsoredIt’s game over for Central BanksCentral banks are losing control. Inflation isn’t fixed, debt is exploding, and stocks have never looked more ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SciSparc Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share SciSparc With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access